always inspiring more...

Symrise AG H1 2017

symrise 🌍

Tobias Erfurth & Annika Stern, Investor Relations August 2017

Financial Highlights H1 2017

Symrise again with industry leading organic growth





Sales by Region Positive dynamics in Latin America and EAME





Group Strong organic growth of 5.2%



Sales In € m					Comments
1,462.5 H1 2016	+5.2% 76.0 Organic growth	-2.3% -33.7 Portfolio	+0.7% 10.4	+3.6% 1,515.3 H1 2017	 Grganic growth of 5.2% in line with mid-term guidance despite high comparables. Portfolio effect of -2.3% stemming from Pinova Inc. divestment, partly offset by acquisitions of Nutra Canada and Nutraceutix. FX effect back to neutral.

Scent & Care Symposities Symposities Symposities Symposities Symposities and Weaker demand in some application areas

Sales In € m					Comments
667.8 H1 2016	+1.1% 7.4 Organic growth	-7.6% -50.7 Portfolio	+2.1% 13.8 <i>FX</i>	-4.4% 638.2 H1 2017	 Grganic growth slower against high comparables from prior year. Good dynamics in Fine Fragrances and Cosmetic Ingredients offset by weaker demand in Beauty Care. Scent & Care recovery expected in the second half of 2017 due to project pipeline and core list wins.

Flavor High growth driven by Sweet and Beverages



Sales In € m					Comments
517.8	+8.6% 44.7		-1.5% -7.6	+7.2% 5554.8	Growth driven by strong demand for sweets and new business with beverages. Strong demand for savory applications in Western Europe and North Africa.
H1 2016	Organic growth	Portfolio	FX	H1 2017	

Nutrition *Continued high growth rates*



Sales In € m					Comments
277.0 H1 2016	+8.6% 23.9 Organic growth	+6.2% 17.0	+1.5% 4.3	+16.3% 322.2 H1 2017	 Diana Pet Food: Strong dynamics in all regions. Diana Food: Especially high demand in North and South America. Portfolio growth coming from the acquisitions of Nutra Canada and Nutraceutix.

EBITDA Remains on a healthy margin level



EBITDA In € m				Comments
EBITDA- Margin +20. -11 323.3 323.3 Group S& H1 2016	8 3.1	8.3 Nutrition	+21.3% 322.9 Group H1 2017	 Ongoing investments in growth, especially R&D (+9.8%) and S&M (+4.1%). EBITDA decline in S&C due to Pinova Inc. divesture as well as weak Beauty Care demand offset by strong Flavor and Nutrition performance. S&C recovery in H2 expected due to promising project pipeline and core list wins. Flavor margin with 22.2% on a high and healthy level. Nutrition high margin and strong EBITDA contribution.

P&L Stable bottom-line



Short P&L In € m					Comments
	H1 2016	H1 2016 N	H1 2017	Change	_
Gross profit	607.6	612.3	627.8	2.5%	Nearly stable gross margin of 41.4% (normalized H1 2016: 41.9%) despite
EBITDA	312.7	323.3	322.9	-0.1%	raw material price increases reflects robustness of business model.
Depreciation	42.6	42.6	44.0	3.3%	— Increase in depreciation <i>in line with</i>
Amortization	56.0	56.0	54.4	-2.9%	higher investment volume.
EBIT	214.1	224.7	224.6	-0.1%	Financial result slightly below normalized H1 2016 mainly due to FX
Financial result	-24.3	-22.1	-23.0	-4.1%	gains in PY.
ЕВТ	189.8	202.7	201.6	-0.6%	_
Net income	133.8	142.0	141.8	-0.1.%	
EPS in €	1.03	1.09	1.09	-0.1%	

Cash Flow Improved working capital management supports operating cash flow



Balance Sheet *Healthy capital structure*





* Balance sheet 2016 adjusted for Nutraceutix purchase price allocation.

Acquisition Cobell, UK Expansion of market presence in beverages



Cobell supplies natural ingredients and juice components for the beverage industry

Sales 2016: € 58 million.

One of the fastest growing suppliers for the beverage industry, thanks to close customer retention.

The combination of Symrise and Cobell corresponds to our successful business model in Germany, which will lead to a unique platform of beverage solutions.

Development and supply chain under one roof.

Targeted investment in promising British beverages market.



Expanded Presence in Asia

Development centers opened in Singapore and India



New Innovation and Technology Center in Singapore	New Creative Center in Mumbai
<text><text><text></text></text></text>	Development studio and laboratories for Fragrance, Cosmetic Ingredients and Oral Care. Complementing existing center in Chennai. Indian economy promises good long-term growth prospects.

Capacity Expansion at Diana Food New Nutrition site in Georgia, USA



Construction of a new production site

- Investment of \$ 50 million.
- *New factory on a 40-hectare site for manufacturing of natural, declaration-free food ingredients and product solutions.*
- Scheduled for completion in 2019.



Planned Diana Foods production facility, Banks County, Georgia, USA



Outlook Symrise optimistic for fiscal year 2017



Consequent implementation of corporate strategy in first half-year

Competencies and market presence *further enhanced, for example through the acquisition of Cobell and the implementation of various strategic initiatives.*

Accelerated growth in Emerging Markets.



Unique profile: *Diversified application portfolio with market-leading positions.*

Strong market dynamics in Flavor & Nutrition / Recovery of demand in Scent & Care expected.

Further investments to expand capacity and improve processes are on track.

Targets For 2017 And Beyond symrise Guidance increased: EBITDA margin 2017 now above 20 %



Symrise AG Investor relations



Financial Calendar

November 8, 2017 9M 2017 results

Contact

Symrise AG Investor Relations Mühlenfeldstraße 1 37603 Holzminden, Germany

Tobias Erfurth *tobias.erfurth@symrise.com*

Annika Stern annika.stern@symrise.com

Christian Haverkamp christian.haverkamp@symrise.com

This document contains forward-looking statements, which are based on the current estimates and assumptions by the corporate management of Symrise AG. Future performance and the results actually achieved by Symrise AG and its affiliated companies depend on a number of risks and uncertainties and may therefore differ materially from the forward-looking statements. Many of these factors are outside Symrise's control and cannot be accurately estimated in advance, such as the future economic environment and the actions of competitors and others involved in the marketplace. Symrise neither plans nor undertakes to update any forward-looking statements.